Bone metabolism during long-term treatment with imatinib

被引：7
作者：
O'Sullivan, Susannah [1 ]
Horne, Anne [1 ]
Wattie, Diana [1 ]
Porteous, Fran [2 ]
Gamble, Greg [1 ]
Browett, Peter [2 ]
Grey, Andrew [1 ]
机构：
[1] Univ Auckland, Dept Med, Auckland, New Zealand
[2] Univ Auckland, Dept Mol Med & Pathol, Auckland, New Zealand
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷 / 08期
关键词：
CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; SECONDARY HYPERPARATHYROIDISM; RECEIVING IMATINIB; MINERAL DENSITY; MESYLATE; GROWTH; CHILDREN; DASATINIB; NILOTINIB;
D O I：
10.3109/10428194.2012.760734
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1783 / 1785
页数：3
相关论文
共 24 条
[1]   Sunitinib-induced hyperparathyroidism [J].
Baldazzi, Valentina ;
Tassi, Renato ;
Lapini, Alberto ;
Lunghi, Alice ;
Garofoli, Eleonora ;
Caruso, Salvatore ;
Carini, Marco ;
Mazzanti, Roberto .
CANCER, 2012, 118 (12) :3165-3172
[2]   Imatinib has adverse effect on growth in children with chronic myeloid leukemia [J].
Bansal, Deepak ;
Shava, Upender ;
Varma, Neelam ;
Trehan, Amita ;
Marwaha, R. K. .
PEDIATRIC BLOOD & CANCER, 2012, 59 (03) :481-484
[3]   Altered bone and mineral metabolism in patients receiving imatinib mesylate [J].
Berman, E ;
Nicolaides, M ;
Maki, RG ;
Fleisher, M ;
Chanel, S ;
Scheu, K ;
Wilson, BA ;
Heller, G ;
Sauter, NP .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (19) :2006-2013
[4]   Practical management of patients with chronic myeloid leukemia receiving imatinib [J].
Deininger, MWN ;
O'Brien, SG ;
Ford, JM ;
Druker, BJ .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1637-1647
[5]   Imatinib mesylate (Gleevec®) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity [J].
Dib, Iman El Hajj ;
Gallet, Marlene ;
Mentaverri, Romuald ;
Sevenet, Nicolas ;
Brazier, Michel ;
Kamel, Said .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 551 (1-3) :27-33
[6]   Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism [J].
Grey, Andrew ;
O'Sullivan, Susannah ;
Reid, Ian R. ;
Browett, Peter .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2494-2495
[7]   Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia [J].
Jonsson, Sofia ;
Olsson, Bob ;
Ohlsson, Claes ;
Lorentzon, Mattias ;
Mellstrom, Dan ;
Wadenvik, Hans .
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (07) :1101-1103
[8]   Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib [J].
Jonsson, Sofia ;
Standal, Therese ;
Olsson, Bob ;
Mellstrom, Dan ;
Wadenvik, Hans .
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (05) :550-552
[9]   Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial [J].
Kantarjian, Hagop ;
Pasquini, Ricardo ;
Hamerschlak, Nelson ;
Rousselot, Philippe ;
Holowiecki, Jerzy ;
Jootar, Saengsuree ;
Robak, Tadeusz ;
Khoroshko, Nina ;
Masszi, Tamas ;
Skotnicki, Aleksander ;
Hellmann, Andrzej ;
Zaritsky, Andrey ;
Golenkov, Anatoly ;
Radich, Jerald ;
Hughes, Timothy ;
Countouriotis, Athena ;
Shah, Neil .
BLOOD, 2007, 109 (12) :5143-5150
[10]   Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure [J].
Khoury, H. Jean ;
Cortes, Jorge E. ;
Kantarjian, Hagop M. ;
Gambacorti-Passerini, Carlo ;
Baccarani, Michele ;
Kim, Dong-Wook ;
Zaritskey, Andrey ;
Countouriotis, Athena ;
Besson, Nadine ;
Leip, Eric ;
Kelly, Virginia ;
Bruemmendorf, Tim H. .
BLOOD, 2012, 119 (15) :3403-3412
123